glp-1 drugs mexico The Future of Weight Loss: Combining ESG and Obesity drug cuts opiate craving

Discover trends in diabetes care, weight-loss demand, pricing, and generics.

Allulose in human diet: the knowns and the unknowns - Volume 128 Issue 2

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

however, GLP-1 receptor agonists were associated with a higher risk of discontinuation of endoscopy, possibly owing to a higher risk of retained gastric content

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring